Company Overview

IMUNON is a fully integrated, clinical stage biotechnology company focused on advancing a portfolio of innovative treatments that harness the body’s natural mechanisms to generate safe, effective, and durable responses across a broad array of human diseases, constituting a differentiating approach from conventional therapies.

Read More Investor Presentation Corporate Fact Sheet

Latest News

IMUNON Enters Cooperative Research and Development Agreement with National Cancer Institute to Advance Clinical Development of IMNN-001

September 10, 2026

IMUNON Announces Full Agenda and Speaker Lineup Ahead of 2026 R&D Day Highlighting IMNN-001 Clinical Progress

September 9, 2026

IMUNON to Host 2026 R&D Day Highlighting Phase 3 OVATION 3 Trial and the Clinical Potential of IMNN-001

August 26, 2026

Financial Events

Imunon Second Quarter 2026 Financial Results

August 11, 2026 at 11:00 AM EDT

Presentation at the Zacks SCR Life Sciences Virtual Investor Forum

June 25, 2026